Application of the Original L-Ornithine-L-Aspartate in Patients with Complex Cardiovascular Disease and Type 2 Diabetes Mellitus

Authors

  • V.Yu. Zharynova State Institution «Institute of Gerontology named after D.F. Chebotariov of National Academy of Medical Sciences of Ukraine», Kyiv
  • K.N. Ihrunova State Institution «Institute of Gerontology named after D.F. Chebotariov of National Academy of Medical Sciences of Ukraine», Kyiv
  • L.A. Bodretska State Institution «Institute of Gerontology named after D.F. Chebotariov of National Academy of Medical Sciences of Ukraine», Kyiv
  • V.P. Chyzhova State Institution «Institute of Gerontology named after D.F. Chebotariov of National Academy of Medical Sciences of Ukraine», Kyiv
  • I.A. Samots State Institution «Institute of Gerontology named after D.F. Chebotariov of National Academy of Medical Sciences of Ukraine», Kyiv
  • Zh.S. Butynets State Institution «Institute of Gerontology named after D.F. Chebotariov of National Academy of Medical Sciences of Ukraine», Kyiv
  • A.Yu. Haletskyi State Institution «Institute of Gerontology named after D.F. Chebotariov of National Academy of Medical Sciences of Ukraine», Kyiv
  • N.N. Benkovska State Institution «Institute of Gerontology named after D.F. Chebotariov of National Academy of Medical Sciences of Ukraine», Kyiv
  • V.O. Tabakovych-Vatseba State Institution «Institute of Gerontology named after D.F. Chebotariov of National Academy of Medical Sciences of Ukraine», Kyiv

DOI:

https://doi.org/10.22141/2224-0721.8.72.2015.72335

Keywords:

diabetes mellitus, cardiovascular disease, hepatoprotectors, non-alcoholic fatty liver disease

Abstract

The article deals with the treatment of nonalcoholic fatty liver disease as a complication in patients with complex cardiovascular disease and type 2 diabetes mellitus. The data from the studies on the effect of Hepa-Merz® on the functional state of the liver, endothelium, blood rheology, the state of the capillary circulation, endotoxemia markers and clinical status in these patients are presented. The findings confirm the possibility of the influence of Hepa-Merz® on the functional disorders of the liver in patients with complex cardiovascular disease and type 2 diabetes mellitus.

Downloads

Download data is not yet available.

References

Мубаракшина О.А. Гепатопротекторы: сравнительная характеристика и аспекты клинического использования // Медицинский вестник. — 2008. — № 34.

Оковитый С.В. Клиническая фармакология гепатопротекторов // Практик. — 2002. — № 3.

Передерий В.Г., Чернявский В.В., Шипулин В.П. Сравнительная эффективность применения гепатопротекторов при хронических диффузных заболеваниях печени // Сучасна гастроентерологія. — 2008. — № 3. — С. 81-83.

Arab J.P., Candia R., Zapata R. et al. Management of nonalcoholic fatty liver disease:an evidence-based clinical practice review // World J. Gastroenterol. — 2014. — 20 (34). — 12182-201. doi:10.3748/wjg.v20.i34.12182.

Bass N.M., Mullen K.D., Sanyal A. et al. Rifaximin treatment in hepatic encephalopathy // New England Journal of Medicine. — 2010. — 362 (12). — 1071-1081.

Clark J.M. The epidemiology of nonalcoholic fatty liver disease in adults // J. Clin. Gastroenterol. — 2006 Mar. — 40, Suppl. 1. — S5-10.

Córdoba J., López-Hellín J., Planas M. et al. Normal protein diet for episodic hepatic encephalopathy: Results of a randomized study // J. Hepatol. — 2004. — 41. — 38-43.

Farrell G.C., Larter C.Z. Nonalcoholic fatty liver disease: from steatosis to cirrhosis // Hepatology. — 2006 Feb. — 43 (2, Suppl. 1). — S99-S11.

Jalan R., Wright G., Davies N.A., Hodges S.J. L-Ornithine phenylacetate (OP): a novel treatment for hyperammonemia and hepatic encephalopathy // Med. Hypotheses. — 2007. — 69. — 1064-69.

Leise M., Poterucha J., Kamath P. Management of Hepatic Encephalopathy in the Hospital // Clin. Proc. — 2014. — 89 (2). — 241-253.

Malaguarnera M., Gargante M.P., Cristaldi E. et al. Acetyl-L-carnitine treatment in minimal hepatic encephalopathy // Digestive Diseases and Sciences. — 2008. — 53 (11). — 3018-3025.

McPhail M., Leech R., Grover V. et al. Modulation of neural activation following treatment of hepatic encephalopathy // Neurology. — 2013. — 80 (11). — P. 1041-1047.

Miyake M., Kirisako T. Randomised controlled trial of the effects of L-ornithine on stress markers and sleep quality in healthy workers // Nutr. J. — 2014. — 13. — P. 53-55.

Neuschwander-Tetri B.A., Caldwell S.H. Nonalcoholic steatohepatitis: Summary of an AASLD Single Topic Conference // Hepatology. — 2003. — 37 (5). — 1202-1219.

Ong J.P., Elariny H., Collantes R. et al. Predictors of nonalcoholic steatohepatitis and advanced fibrosis in morbidly obese patients // Obes. Surg. — 2005 Mar. — 15 (3). — 310-5.

Rinella M.E. Nonalcoholic fatty liver disease: a systematic review // JAMA. — 2015 Jun 9. — 313 (22). — 2263-73. doi:10.1001/jama.2015.5370.

Sharma P., Sharma B.C., Puri V., Sarin S.K. An open-label randomized controlled trial of lactulose and probiotics in the treatment of minimal hepatic encephalopathy // European Journal of Gastroenterology and Hepatology. — 2008. — 20 (6). — 506-511.

Skowrońska M., Albrecht J. Alteration of blood brain barrier function in hyperammonemia // Neurotox. res. — 2012. — 21 (2). — P. 236-244.

Thompson J.R. Treatment guidelines for hepatic encephalopathy // Pharmacotherapy. — 2010. — 30 (5). — 4S-9S.

Zhang Y., Janssen P., WinglerK. et al. Modulating endothelial nitric oxide synthase:a new cardiovascular therapeutic strategy // Am. J. Physiol. Heart Circ. Physiol. — 2011. — 301. — H634-H646.

Published

2021-11-30

How to Cite

Zharynova, V., Ihrunova, K., Bodretska, L., Chyzhova, V., Samots, I., Butynets, Z., Haletskyi, A., Benkovska, N., & Tabakovych-Vatseba, V. (2021). Application of the Original L-Ornithine-L-Aspartate in Patients with Complex Cardiovascular Disease and Type 2 Diabetes Mellitus. INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine), (8.72), 33–41. https://doi.org/10.22141/2224-0721.8.72.2015.72335

Issue

Section

Original Researches